The Manufacturers Life Insurance Company Makes New Investment in Agios Pharmaceuticals, Inc. $AGIO

Key Points

• The Manufacturers Life Insurance Company initiated a position in Agios Pharmaceuticals, purchasing 37,727 shares valued at approximately $1.4 million. Other institutions also increased their holdings or established new positions in the biopharmaceutical company.
• Analysts maintain a generally positive outlook, with Agios receiving a consensus “Moderate Buy” rating and an average price target of $41.25. Several firms recently raised their targets, including HC Wainwright to $55 and Citigroup to $52.
• Agios reported a quarterly loss of $1.69 per share, slightly worse than the expected $1.65 loss, although revenue of $44.75 million exceeded expectations of $26.39 million. The stock opened at $33.10, below its 52-week high of $46.00.

The Manufacturers Life Insurance Company acquired a new position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 37,727 shares of the biopharmaceutical company's stock, valued at approximately $1,400,000. The Manufacturers Life Insurance Company owned approximately 0.06% of Agios Pharmaceuticals at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of AGIO. Sei Investments Co. raised its stake in Agios Pharmaceuticals by 342.8% during the first quarter. Sei Investments Co. now owns 63,550 shares of the biopharmaceutical company's stock valued at $2,150,000 after purchasing an additional 49,198 shares in the last quarter. SCS Capital Management LLC bought a new position in Agios Pharmaceuticals during the second quarter valued at $22,743,000. State of New Jersey Common Pension Fund D purchased a new position in shares of Agios Pharmaceuticals in the 4th quarter worth $1,291,000. Seven Fleet Capital Management LP purchased a new position in shares of Agios Pharmaceuticals in the 4th quarter worth $864,000. Finally, GW&K Investment Management LLC increased its holdings in shares of Agios Pharmaceuticals by 41.5% in the 4th quarter. GW&K Investment Management LLC now owns 1,207,301 shares of the biopharmaceutical company's stock worth $32,863,000 after buying an additional 354,359 shares during the last quarter.

Insider Transactions at Agios Pharmaceuticals

In other news, insider Sarah Gheuens sold 30,000 shares of Agios Pharmaceuticals stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $30.48, for a total transaction of $914,400.00. Following the completion of the sale, the insider directly owned 54,645 shares in the company, valued at approximately $1,665,579.60. This trade represents a 35.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.40% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. HC Wainwright upped their target price on shares of Agios Pharmaceuticals from $52.00 to $55.00 and gave the company a "buy" rating in a research report on Thursday, July 30th. Truist Financial dropped their price target on Agios Pharmaceuticals from $41.00 to $39.00 and set a "buy" rating for the company in a research report on Friday, July 31st. JPMorgan Chase & Co. boosted their price objective on Agios Pharmaceuticals from $31.00 to $34.00 and gave the stock a "neutral" rating in a research note on Friday, August 7th. Citigroup upped their price objective on Agios Pharmaceuticals from $46.00 to $52.00 and gave the company a "buy" rating in a research report on Friday, July 31st. Finally, Bank of America raised their price objective on Agios Pharmaceuticals from $40.00 to $46.00 and gave the company a "buy" rating in a research note on Tuesday, July 7th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $41.25.

Agios Pharmaceuticals Price Performance

Agios Pharmaceuticals stock opened at $33.10 on Friday. Agios Pharmaceuticals, Inc. has a 1-year low of $22.24 and a 1-year high of $46.00. The firm has a market capitalization of $1.98 billion, a P/E ratio of -4.72 and a beta of 0.60. The company's 50-day moving average is $35.64 and its 200 day moving average is $31.84.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.65) by ($0.04). The business had revenue of $44.75 million for the quarter, compared to analysts' expectations of $26.39 million. Agios Pharmaceuticals had a negative net margin of 418.24% and a negative return on equity of 35.67%. Research analysts anticipate that Agios Pharmaceuticals, Inc. will post -5.82 earnings per share for the current fiscal year.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company's scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios's lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source